Genetic Therapy Inc. of Gaithersburg, Md., named MichaelCasey as its new chief operating officer and president. Caseywas formerly president of McNeil Pharmaceutical, a division ofJohnson & Johnson. M. James Barrett, president and chiefexecutive officer of Genetic Therapy since 1987, continues asthe company's CEO and assumes the title of chairman of theboard.
Jason Rubin has been appointed vice president of corporatecommunications at Cephalon Inc. of West Chester, Pa. Rubin hadbeen vice president of communications at Immunex Corp. ofSeattle. Immunex has promoted Valoree Dowell to that positionfrom director of communications, effective July 1.
Bio-Imaging Technologies Inc. of West Trenton, N.J., promotedWilliam Wegener to medical director. He had been thecompany's director of new technologies.
Clare Clifford has joined Repligen Corp. as director of corporatecommunications. Prior to joining the Cambridge, Mass.,company, she was vice president and director of Hill &Knowlton Inc.'s bioscience group in Waltham, Mass.
Targeted Genetics Corp. of Seattle has appointed ThomasReynolds director of development. Reynolds joins TargetedGenetics from Somatix Therapy Corp., where he was a researchscientist.
Karen Yamamoto has been promoted to director of molecularbiology at privately held MedClone Inc. Yamamoto had been asenior scientist at the Los Angeles company.
Biocyte Corp. of Stamford, Conn. has hired AnnMarie Quintaglieas director of marketing and Cindy McIntyre as director ofoperations. Quintaglie joins Biocyte from Johnson & Johnson'sadvanced care products division, where she served as franchisedirector for Monistat 7. McIntyre had been with the AmericanRed Cross as the director of Connecticut region tissue services.
Ascent Pharmaceuticals Inc. of Billerica, Mass., appointedRobert Baldini to its board of directors. Baldini is senior vicepresident and general manager of marketing and sales for KeyPharmaceuticals Inc., a division of Schering-Plough.
Genzyme Corp. of Cambridge, Mass., has appointed JohnMcPherson, its vice president of development, as officer of thecorporation. Larry Soll, chief executive and chairman of theboard of Synergen Inc., has been named to a seat onImmuLogic Pharmaceutical Corp.'s board of directors. Sollreplaces James Bochnowski of Delphi Bioventures, an initialventure capital investor in ImmuLogic of Waltham, Mass.
(c) 1997 American Health Consultants. All rights reserved.